Coronavirus disease 2019 (COVID-19) poses a great challenge for the treatment of cancer patients. It presents as a severe respiratory infection in aged individuals, including some lung cancer patients. COVID-19 may be linked to the progression of aggressive lung cancer. In addition, the side effects of chemotherapy, such as chemotherapy resistance and the acceleration of cellular senescence, can worsen COVID-19. Given this situation, we investigated the role of paclitaxel (a chemotherapy drug) in the cell proliferation, apoptosis, and cellular senescence of gefitinib-resistant non-small-cell lung cancer (NSCLC) cells (PC9-MET) to clarify the underlying mechanisms.

中文翻译：

---

紫杉醇对吉非替尼耐药的非小细胞肺癌细胞生长抑制作用的机制。

2019 年冠状病毒病 (COVID-19) 对癌症患者的治疗提出了巨大挑战。它表现为老年人（包括一些肺癌患者）的严重呼吸道感染。COVID-19 可能与侵袭性肺癌的进展有关。此外，化疗的副作用，如化疗耐药和细胞衰老加速，会加重 COVID-19。鉴于这种情况，我们研究了紫杉醇（一种化疗药物）在吉非替尼耐药的非小细胞肺癌 (NSCLC) 细胞 (PC9-MET) 的细胞增殖、凋亡和细胞衰老中的作用，以阐明其潜在机制.